Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Frontiers in Neurology|January 3, 2022
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in MenRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
The Journal of Headache and Pain|March 20, 2022
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen studyRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
Journal of Neurology|May 7, 2025
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
The Journal of Headache and Pain|October 2, 2025
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)Piero Barbanti, Giulia Fiorentini, Cecilia Camarda, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 22, 2024
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real worldEdoardo Caronna, Victor José Gallardo, Gabriella Egeo, et al.
Trials|August 20, 2016
Efficacy of a new technique - INtubate-RECruit-SURfactant-Extubate - "IN-REC-SUR-E" - in preterm neonates with respiratory distress syndrome: study protocol for a randomized controlled trialGiovanni Vento, Roberta Pastorino, Luca Boni, et al.
The Lancet. Respiratory Medicine|July 21, 2020
Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trialGiovanni Vento, Maria Luisa Ventura, Roberta Pastorino, et al.
JAMA Network Open|September 25, 2024
Lung Recruitment Before Surfactant Administration in Extremely Preterm Neonates: 2-Year Follow-Up of a Randomized Clinical TrialFrancesca Gallini, Domenico Umberto De Rose, Roberta Iuliano, et al.
Neurology|January 28, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA CohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Cephalalgia : an International Journal of Headache|June 19, 2026
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Pageof 17